US 12,404,251 B2
Small molecule compound
Bingwei Lu, Stanford, CA (US)
Assigned to Cerepeut, Inc., Stanford, CA (US)
Filed by Cerepeut, Inc., Stanford, CA (US)
Filed on Feb. 26, 2024, as Appl. No. 18/587,753.
Application 18/587,753 is a continuation of application No. 17/537,142, filed on Nov. 29, 2021, granted, now 11,912,669.
Application 17/537,142 is a continuation of application No. 16/647,383, granted, now 11,186,550, issued on Nov. 30, 2021, previously published as PCT/US2018/050689, filed on Sep. 12, 2018.
Claims priority of provisional application 62/558,323, filed on Sep. 13, 2017.
Prior Publication US 2024/0246919 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/95 (2006.01); A61P 9/10 (2006.01); A61P 23/00 (2006.01); A61P 35/00 (2006.01)
CPC C07D 239/95 (2013.01) [A61P 9/10 (2018.01); A61P 23/00 (2018.01); A61P 35/00 (2018.01)] 17 Claims
 
1. A method for treating a neurodegenerative disease or condition associated with mitochondrial dysfunction in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound according to Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or derivative thereof.